For the Inventor, By the Inventor

Enter assignee name

Mochida Pharmaceutical Co., Ltd.

USPTO Granted Patents = 229

CIPO Patents = 11

EPO Patents = 60

Trademarks = 5

Forward Citations = 3,008

Loading Chart...

Loading Chart...

312 inventors (with patents filed for the assignee):

Ei Mochida (41 out of 52 patents)

Kamon Shirakawa (24 out of 24 patents)

Shoji Furusako (16 out of 17 patents)

4. Tsutomu Satoh (15 out of 36 patents)

5. Haruo Ohnishi (15 out of 18 patents)

6. Masahiro Nobuhara (14 out of 14 patents)

7. Kazuo Kato (14 out of 79 patents)

8. Hirosato Fujii (13 out of 13 patents)

9. Yasuo Suzuki (13 out of 27 patents)

10. Toshinori Kanamori (12 out of 12 patents)

11. Motoo Yamagata (11 out of 11 patents)

12. Hiroshi Kosuzume (11 out of 14 patents)

13. Hideki Origasa (10 out of 11 patents)

14. Yuji Matsuzawa (10 out of 21 patents)

15. Yasushi Saito (10 out of 37 patents)

Core Competencies:

Intervertebral Disc Treatment

Crosslinked Alginic Acid

Nerve Regeneration

Eicosapentaenoic Acid

Anti-Presepsin Antibody

Cardiovascular Event Prevention

Non-Alcoholic Steatohepatitis

Photocrosslinkable Alginic Acid

Heterocyclidene Acetamide Derivative

Tetrahydronaphthyl Urea Derivative

Self-Emulsifying Composition

Adhesion-Preventing Composition

229 patents: Sort by Forward Citations

1. 12502375 - Pharmaceutical drug containing heterocyclidene acetamide derivative (2025-12-23),

2. 12491208 - Combination and method for treating subject using alginate (2025-12-09),

3. 12479933 - Crosslinked alginic acid structure (2025-11-25),

4. 12478637 - Method for suppressing intervertebral disc pain (2025-11-25),

5. 12478636 - Composition for treating intervertebral disc (2025-11-25),

6. 12349886 - Retractor (2025-07-08),

7. 12312574 - Polymer-coated crosslinked alginate gel fiber (2025-05-27),

8. 12286414 - Method for producing heterocyclidene acetamide derivative (2025-04-29),

9. 12226544 - Brain damage recovery material (2025-02-18),

10. 12151025 - Freeze-dried alginic acid preparation (2024-11-26),

11. 12134607 - Crystals of tetrahydronaphthyl urea derivative (2024-11-05),

12. 11969437 - Alginate liquid preparation (2024-04-30),

13. 11932708 - Crosslinked alginic acid (2024-03-19),

14. 11911480 - Self-emulsifying composition of ω-3 fatty acid (2024-02-27),

15. 11890145 - Adhesion-preventing composition (2024-02-06),

Mochida Pharmaceutical Co., Ltd. is a leading Japanese pharmaceutical company specializing in the research, development, and manufacturing of innovative healthcare solutions. With a rich history dating back to 1919, Mochida combines scientific expertise with a commitment to improving the well-being of individuals and society. Their diverse product portfolio includes prescription drugs, over-the-counter medications, diagnostic agents, and medical devices. Mochida Pharmaceutical strives to address unmet medical needs by collaborating with global partners and leveraging advanced technology. They aim to contribute to the advancement of healthcare by delivering safe and effective treatments worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

229 Patents

#275 in Tokyo

#619 in Japan

#3,632 in the World

Mochida Pharmaceutical Co., Ltd.

Forward Citations = 3,008

312 inventors:

Ei Mochida (41 out of 52 patents)

Kamon Shirakawa (24 out of 24 patents)

Shoji Furusako (16 out of 17 patents)

4. Tsutomu Satoh (15 out of 36 patents)

5. Haruo Ohnishi (15 out of 18 patents)

Please report any incorrect information to support@idiyas.com

Loading…